How long does it take to develop resistance to ceritinib/ceritinib (Zanda)?

Ceritinib (Ceritinib) is a second-generation ALK inhibitor, commonly used in patients with non-small cell lung cancer (NSCLC) after failure of crizotinib (Crizotinib) treatment. It has significant advantages in overcoming some drug-resistant mutations and can extend patients' progression-free survival (PFS). However, like other targeted drugs, tumor cells will gradually develop resistance under long-term selective pressure, leading to disease progression again.

Clinical studies show that the median progression-free survival of ceritinib is generally 6 to 9 months, some patients can maintain it for more than 1 years, but some patients develop drug resistance after 3 to 4 months of treatment. Therefore, there are individual differences in resistance time, which is affected by factors such as the type of genetic mutation of the patient's tumor, comorbidities, tolerance, and drug compliance. In general, most patients will gradually develop signs of resistance within 1 year of treatment.

The mechanism of resistance to ceritinib is relatively complex, mainly including New mutations in the ALK gene (such as G1202R mutation), activation of alternative pathways (such as EGFR, KIT, MET and other signal enhancements), and changes in the tumor microenvironment. In some patients, tumor cells may continue to proliferate through alternative pathways after ceritinib treatment, leading to disease recurrence. This also explains why resistance time varies from person to person.

When resistance to ceritinib occurs, common responses include replacing third-generationALK inhibitors (such as lorlatinibLorlatinib), or in some cases combining chemotherapy and immunotherapy. At the same time, clinicians usually recommend genetic testing when the disease progresses to clarify the type of drug-resistant mutations so that more accurate subsequent treatment options can be selected. Proper monitoring and timely adjustment of medication can maximize the overall survival of patients.

Reference materials:https://www.drugs.com/